Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer

Translational Oncology

Volumn 6, Issue 5, 2013, Pages 539-545

  Engineer, Diana R ^a,b,c   Burney, Basil O ^a   Hayes, Teresa G ^b   Garcia, Jose M ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; TUMOR GROWTH; WEIGHT REDUCTION;

EID: 84885744371     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13346     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Rosenthal T and Gavras I (2009). Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23, 623-635.
3. Otani A, Takagi H, Suzuma K, and Honda Y (1998). Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82, 619-628.
4. Tamarat R, Silvestre JS, Durie M, and Levy BI (2002). Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways. Lab Invest 82, 747-756.
5. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, et al. (2003). Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112, 67-75.
6. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, and Dzau VJ (1999). Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 84, 876-882.
7. Rivat C, Rodrigues S, Bruyneel E, Piétu G, Robert A, Redeuilh G, Bracke M, Gespach C, and Attoub S (2005). Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)-and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 65, 195-202.
8. Lyall F, Dornan ES, McQueen J, Boswell F, and Kelly M (1992). Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor. J Hypertens 10, 1463-1469.
9. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, and Jonsson JR (1998). Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77, 880-883.
10. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, and Bouck NP (1996). Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98, 671-679.
11. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, and Mitch WE (2009). IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 20, 604-612.
12. Barron TI, Connolly RM, Sharp L, Bennett K, and Visvanathan K (2011). Beta Blockers and breast cancer mortality: a population-based study. J Clin Oncol 29, 2635-2644.
13. Zhou Z, Rahme E, Abrahamowicz M, and Pilote L (2005). Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162, 1016-1023.
14. Freemantle N, Cleland J, Young P, Mason J, and Harrison J (1999). β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318, 1730-1737.
15. Brophy JM, Joseph L, and Rouleau JL (2001). β-Blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134, 550-560.
16. Deshayes F and Nahmias C (2005). Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16, 293-299.
17. Imanishi T, Hano T, and Nishio I (2004). Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 27, 101-108.
18. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, and Yang B (2010). Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 159, 1584-1594.
19. Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, et al. (2003). Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulinlike growth factor I receptor pathway. Cancer Res 63, 6726-6734.
20. Cardinale D, Colombo A, and Cipolla CM (2008). Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 10, 486-495.
21. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, and Robertson JW (1998). Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352, 179-184.
22. Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, and Siddiqui AA (2011). Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 45, e12-e16.
23. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, and Lê MG (2004). Could treatments with β-blockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 52, 53-65.
24. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, and Taïeb A (2008). Propranolol for severe hemangiomas of infancy. N Engl J Med 358, 2649-2651.
25. Lamy S, Lachambre MP, Lord-Dufour S, and Béliveau R (2010). Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 53, 200-208.
26. Wong HP, Ho JW, Koo MW, Yu L, Wu WK, Lam EK, Tai EK, Ko JK, Shin VY, Chu KM, et al. (2011). Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci 88, 1108-1112.
27. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, and DuBois RN (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188.
28. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, and Kuan P (2005). Carvedilol modulates the expression of hypoxia-inducible factor-1α and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail 11, 152-159.
29. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, and Béliveau R (2009). Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60, 438-445.
30. Hyltander A, Daneryd P, Sandström R, Körner U, and Lundholm K (2000). β-Adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer 36, 330-334.
31. Utech AE, Tadros EM, Hayes TG, and Garcia JM (2012). Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 3, 245-251.
32. Bozkurt B, Bolos M, Deswal A, Ather S, Chan W, Mann DL, and Carabello B (2012). New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients-a matter of time for contractility. J Card Fail 18, 183-193.